Commonwealth Equity Services’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Commonwealth Equity Services’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,863	Closed	-$38K	–	2651
2017 Q2	$38K	Sell	3,863 -341	-8%	-$6.97K	﹤0.01%	2436
2017 Q1	$102K	Sell	4,204 -267	-6%	-$6.68K	﹤0.01%	2279
2016 Q4	$144K	Sell	4,471 -223	-5%	-$9.51K	﹤0.01%	2144
2016 Q3	$235K	Buy	4,694 +445	+10%	+$18.5K	﹤0.01%	1891
2016 Q2	$180K	Sell	4,249 -311	-7%	-$16.9K	﹤0.01%	1996
2016 Q1	$300K	Buy	4,560 +84	+2%	+$4.38K	﹤0.01%	1639
2015 Q4	$278K	Buy	4,476 +89	+2%	+$6.26K	﹤0.01%	1656
2015 Q3	$294K	Buy	4,387 +883	+25%	+$72.1K	﹤0.01%	1556
2015 Q2	$341K	Buy	3,504 +1,442	+70%	+$137K	﹤0.01%	1560
2015 Q1	$193K	Buy	+2,062	New	+$175K	﹤0.01%	1940

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Commonwealth Equity Services's MACK Position: Q3 2017 in Review

Commonwealth Equity Services sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 3,863 shares — an estimated $38K sold.

Commonwealth Equity Services first reported a position in MACK in Q1 2015 and held it in 10 quarters. The position peaked at $341K in Q2 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

Commonwealth Equity Services reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Commonwealth Equity Services sold 3,863 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $38K.
Commonwealth Equity Services first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2015 and held it in 10 quarters.
Commonwealth Equity Services's Merrimack Pharmaceuticals, Inc. position peaked at $341K in Q2 2015.
73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Commonwealth Equity Services's 13F filing for Q3 2017, filed 7 Nov 2017.